Effect of NMDA Receptor Blocker Hemantane in Combination with TRPV1 Agonist Capsaicin on Pain Response in Mice

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The TRPV1 ion channel and the NMDA receptor are being studied as targets for analgesics. This study assessed the effects of the TRPV1 agonist capsaicin, the TRPV1 antagonist 4-(3- chloro- 2- pyridinyl)- N- 4-(1,1- dimethylethyl)phenyl- 1- piperazinecarboxamide (BCTC) and the NMDA receptor blocker N-(2- adamantyl)- hexamethyleneimine hydrochloride (hemantane) on pain response controlled by spinal and supraspinal structures of the central nervous system in C57Bl/6 mice. The threshold in the tail flick test was investigated as a pain response controlled by spinal and supraspinal structures of the central nervous system. Licking of the hind paws and jumping response to skin contact with a heated metal surface in the hot plate test were used as behavioral reactions controlled by the brain. In the tail flick test in mice, BCTC (20 mg/kg intraperitoneally) and hemantane (40 mg/kg intraperitoneally) significantly increased the tail flick threshold by 43% and 25% , respectively. Capsaicin (1 mg/kg, subcutaneously) significantly increased the tail flick threshold up to the cut- off time (maximum stimulus time). BCTC decreased the effect of capsaicin by 2.8 times; in this group of animals, no significant change in the tail flick threshold was recorded compared to the control group of mice that were administered solvents. Hemantane decreased the effect of capsaicin by 1.8 times, while the tail flick threshold in this group was significantly 64% higher than in the control group. In the hot plate test, capsaicin, BCTC and hemantane did not have a significant effect on the jumping and hind paw licking latencies. However, hemantane in combination with capsaicin increased the threshold of hind paw licking by 55.5% compared to the control group. Thus, the NMDA receptor blocker hemantane in combination with capsaicin decreases the threshold in the tail flick test and increases the threshold in the hot plate test.

About the authors

E. A. Ivanova

Federal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies"

Email: ivanova_ea@academpharm.ru
Moscow, Russia

A. G. Vasilchuk

Federal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies"

Moscow, Russia

T. A. Voronina

Federal State Budgetary Scientific Institution "Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies"

Moscow, Russia

References

  1. Koivisto A.P., Belvisi M.G., Gaudet R., Szallasi A. // Nat. Rev. Drug Discov. 2022. V. 21. P. 41–59.
  2. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. // Nature. 1997. V. 389. P. 816–824.
  3. Szallasi A., Blumberg P.M. // Pharmacol. Rev. 1999. V. 51. P. 160–211.
  4. Planells-Cases R., Garcia-Sanz N., Morenilla-Palac O., Ferrer-Montiel A. // Pflugers Arch. 2005. V. 451. № 1. P. 151–159.
  5. Deng M., Chen S.R., Pan H.L. // Cell. Mol. Life Sci. 2019 V. 76. № 10. P. 1889–1899.
  6. Carlton S.M., Hargett G.L., Coggeshall R.E. // Neurosci. Lett. 1995. V. 197. № 1. P. 25–28.
  7. Coggeshall R.E., Carlton S.M. // J. Comp. Neurol. 1998. V. 391. № 1. P. 78–86.
  8. Kinkelin I., Bröcker E.B., Koltzenburg M., Carlton S.M. // Neurosci. Lett. 2000. V. 283. № 2. P. 149–152.
  9. Ma Q.P., Hargreaves R.J. // Neuroscience. 2000. V. 101. № 3. P. 699–707.
  10. Du J., Koltzenburg M., Carlton S.M. // Pain. 2001. V. 89. № 2–3. P. 187–198.
  11. Lawand N.B., Willis W.D., Westlund K.N. // Eur. J. Pharmacol. 1997. V. 324. № 2–3. P. 169–177.
  12. Zhou S., Bonasera L., Carlton S.M. // Neuroreport. 1996. V. 7. № 4. P. 895–900.
  13. Christoph T., Reissmüller E., Schiene K., Englberger W., Chizh B.A. // Brain Res. 2005. V. 1048. № 1–2. P. 218–227.
  14. Lee J., Saloman J.L., Weiland G., Auh Q.S., Chung M.K., Ro J.Y. // Pain. 2012. V. 153. № 7. P. 1514–1524.
  15. Zou X., Lin Q., Willis W.D. // Neuroscience. 2002. V. 115. № 3. P. 775–786.
  16. Иванова Е.А., Васильчук А.Г., Воронина Т.А. // Бюл. эксп. биол. 2024. Т. 177. № 2. С. 200–204.
  17. Иванова Е.А., Матюшкин А.И., Воронина Т.А. // Acta Naturae. 2023. Т. 15. № 1. С. 42–50.
  18. Grijalva C.V., Levin E.D., Morgan M, Roland B., Martin F.C. // Physiol. Behav. 1990. V. 48. № 4. P. 495–500.
  19. Giglio C.A., Defino H.L., da-Silva C.A., de-Souza A.S., Del Bel E.A. // Braz. J. Med. Biol. Res. 2006. V. 39. № 12. P. 1613–1623.
  20. King T.E., Joynes R.L., Grau J.W. // Behav. Neurosci. 1997. V. 111. № 4. P. 754–767.
  21. Valenzano K.J., Grant E.R., Wu G., Hachicha M., Schmid L., Tafesse L., Sun Q., Rothste­yn Y., Francis J., Limberis J., Malik S., Whittemore E.R., Hodgeset D. // J. Pharmacol. Exp. Ther. 2003. V. 306. № 1. P. 377–386.
  22. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Traffon J., Petersen-Zeitz K.R., Koltzenburg M., Basbaum A.I., Julius D. // Science. 2000. V. 288. № 5464. P. 306–313.
  23. Воронина Т.А., Гузеватых Л.С. // Методические рекомендации по изучению анальгетической активности лекарственных средств. В кн. Руководство по проведению доклинических исследований лекарственных средств. Ч. 1. М.: Гриф и К., 2012. С. 197–218.
  24. Espejo E.F., Mir D. // Behav. Brain Res. 1993. V. 56. № 2. P. 171–176.
  25. Sanchez J.F., Krause J.E., Cortright D.N. // Neuroscience. 2001. V. 107. № 3. P. 373–381.
  26. Ji R.R., Kohno T., Moore K.A., Woolf C.J. // Trends Neurosci. 2003. V. 26. P. 696–705.
  27. Sato K., Kiyama H., Park H.T., Tohyama M. // Neuroreport. 1993. V. 4. № 11. P. 1263–1265.
  28. Blanke M.L., Van Dongen A.M.J. // Activation Mechanisms of the NMDA Receptor. In: Biology of the NMDA Receptor / Ed. Van Dongen A.M. Boca Raton (FL): CRC Press/Taylor & Francis, 2009. Chapter 13.
  29. Елишанская М.В., Соболевский А.И., Вальдман Е.А., Ходоров Б.И. // Эксперим. и клин. фармакол. 2001. Т. 64. № 1. С. 18–21.
  30. Pastoriza L.N., Morrow T.J., Casey K.L. // Pain. 1996. V. 64. V. 1. P. 11–17. https://doi.org/10.1016/0304-3959(95)00070-4
  31. Rigby M., Heavens R.P., Smith D., O’Donnell R., Hill R.G., Sirinathsinghji D.I.S. // Distribution of NMDA receptors in brain and spinal cord. In: NMDA Antagonists as Potential Analgesic Drugs. Progress in Inflammation Research. Birkhäuser, Basel, 2002. P. 45–65.
  32. Wu L.J., Zhuo M. // Neurotherapeutics. 2009. V. 6. № 4. P. 693-702.
  33. Иванова Е.А., Матюшкин А.И., Воронина Т.А. // Хим.-фарм. журн. 2021. Т. 55. № 9. С. 3-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russian Academy of Sciences

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).